| A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND. 191 AE Hay, A Murugesan, AM DiPasquale, T Kouroukis, I Sandhu, V Kukreti, ... Leukemia & lymphoma 57 (6), 1463-1466, 2016 | 41 | 2016 |
| Evaluation of a Low‐Threshold/High‐Tolerance Methadone Maintenance Treatment Clinic in Saint John, New Brunswick, Canada: One Year Retention Rate and Illicit Drug Use TKS Christie, A Murugesan, D Manzer, MV O′ Shaughnessey, ... Journal of addiction 2013 (1), 753409, 2013 | 25 | 2013 |
| Antimyeloma potential of caffeic acid phenethyl ester and its analogues through Sp1 mediated downregulation of IKZF1-IRF4-MYC Axis A Murugesan, G Lassalle-Claux, L Hogan, E Vaillancourt, A Selka, ... Journal of Natural Products 83 (12), 3526-3535, 2020 | 13 | 2020 |
| Anti-hyperglycemic activity of HPLC-fractionated Momordica charantia seed extract enriched in a novel napin-like protein in experimental diabetic rats and its validation with … A Murugesan, SKR Yadav, A Dixit Current Research in Biotechnology 4, 179-189, 2022 | 10 | 2022 |
| Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy S Grieve, N Puvvada, A Phinyomark, K Russell, A Murugesan, E Zed, ... Nanomedicine 16 (24), 2175-2188, 2021 | 9 | 2021 |
| Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of JBR. 10 S Grieve, K Ding, J Moore, M Finniss, A Ray, M Lees, F Hossain, ... ESMO open 5 (2), e000679, 2020 | 5 | 2020 |
| A pharmacogenetic analysis of the Canadian Cancer Trials Group MY. 10 clinical trial of maintenance therapy for multiple myeloma M Han, A Murugesan, NJ Bahlis, K Song, D White, C Chen, MD Seftel, ... Blood, The Journal of the American Society of Hematology 128 (5), 732-735, 2016 | 5 | 2016 |
| A pharmacogenetic study of the NCIC CTG clinical trial my. 10: single nucleotide polymorphisms, prognosis, and predicting benefit from imid® compound maintenance therapy … M Han, A Murugesan, NJ Bahlis, K Song, D White, C Chen, MD Seftel, ... Blood 126 (23), 2960, 2015 | 1 | 2015 |
| Anti diabetic protein A Dixit, A Vashishta, T Sahu, SK Choudhary, A Murugesan US Patent 8,669,348, 2014 | 1 | 2014 |
| Peptides for the treatment of resorptive bone disease A Murugesan, A Reiman US Patent 11,884,709, 2024 | | 2024 |
| P081: Enhancing minimally invasive minimal residual disease detection of multiple myeloma using cell-free DNA whole-genome sequencing D Abelman, M Thiagarajah, F Beaudry, J Eagles, S Pederson, J Bruce, ... Genetics in Medicine Open 2, 100963, 2024 | | 2024 |
| Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma DD Abelman, J Eagles, S Pedersen, A Danesh, D Croucher, JP Bruce, ... Blood 142 (Supplement 1), 4693-4693, 2023 | | 2023 |
| Compositions, methods and uses of combination treatments for blood cancers A Murugesan, A Reiman US Patent App. 17/911,302, 2023 | | 2023 |
| Compositions and methods for inhibiting blood cancer cell growth A Murugesan, A Reiman, M Touaibia US Patent App. 17/604,508, 2022 | | 2022 |
| Peptides for the treatment of resorptive bone disease A Murugesan, A Reiman US Patent 10,954,278, 2021 | | 2021 |
| Compositions and methods for inhibiting blood cancer cell growth A Murugesan, A Reiman, M Touaibia US Patent App. 16/757,595, 2020 | | 2020 |
| Novel anti-myeloma potential of CAPE analogs: Downregulation of IKZF1-IRF4-MYC axis A Murugesan, G Lasalle-Claux, L Hogan, E Vaillancourt, A Selka, ... Cancer Research 80 (16_Supplement), 6559-6559, 2020 | | 2020 |
| Detecting minimal residual disease in multiple myeloma: Challenges and prospects for the integration of novel approaches in clinical practice. K Sarty, B Robinson, S Campbell, T Reiman, A Murugesan Oncology Exchange 16 (4), 2017 | | 2017 |
| TRPV6 calcium channel peptide antagonists as novel antimyeloma and antiresorptive agents A Murugesan, P Tremblay, M Han, B Ray, T Lutes, T Reiman Cancer Research 76 (14_Supplement), 3791-3791, 2016 | | 2016 |
| The analysis of TRPV6 expression in lymphoid tumours AM DiPasquale, T Rahmeh, L Andrew, J Agar, K Miller, M Finniss, ... Cancer Research 76 (14_Supplement), 3405-3405, 2016 | | 2016 |
